By Lisa Kerner
Charlotte, N.C., Nov. 13 - Cerenis Therapeutics SA said it closed a $53.5 million round of series B financing, one of the largest private equity deals in biotechnology this year.
TVM Capital led the financing round, joined by OrbiMed and previous investors Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures and NIF SMBC Ventures.
The financing will be used to advance research and clinical development of the company's product candidates, including its lead compound Cerenis HDL, a synthetic form of high-density lipoprotein, or "good cholesterol," that facilitates the removal of excess cholesterol from the body.
Cerenis is a privately held pharmaceutical research and development company based in Toulouse, France.
| Issuer: | Cerenis Therapeutics SA
|
| Issue: | Series B financing
|
| Amount: | $53.5 million
|
| Investors: | TVM Capital (lead), OrbiMed, Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures, NIF SMBC Ventures.
|
| Announcement date: | Nov. 13
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
